Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7

Lilly's performance-based plans for Trulicity may be harder to sustain if Novo's competing once-weekly GLP-1 agonist semaglutide is approved in December, following superiority in a head-to-head diabetes study.

Metabolic Disorders Clinical Trials Market Intelligence

Liver Cancer: What's Close To The Market

The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.

Cancer Approvals Clinical Trials

Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way

FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.

Cardiovascular Market Intelligence Complete Response Letters
Advertisement

Time Is Of The Essence As Teva Considers European Assets Bids

Drug makers and private equity firms expected to submit their offers soon for Teva's oncology and pain businesses in Europe as the Israeli company bids to reduce debt by $5bn by the end of 2017.

M & A Cancer Deals


 Recent Tweets from Scrip


Commercial Explore this Topic

Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.

Business Strategies Regulation Cancer

New Beginnings – How The Big Players Dominate Clinical Trial Starts

AstraZeneca started the greatest number of clinical studies in 2016, finds Trialtrove's latest review, but a new kid on the block, the Chinese company Jiangsu Hengrui Medicine, is nipping at the heels of big pharma in the lists of busiest trial starters.

Clinical Trials Companies Research & Development

Where Will CNS Drug Development Go In 2018?

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

Neurology Business Strategies

Agenovir: Using Gene Editing To Kill Viral DNA

Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.

StartUps and SMEs Business Strategies

The Eyes Have It For Shire With Lifitegrast Filing In Europe

The drug, marketed across the Atlantic as Xiidra, has already made significant inroads in the US dry eye market which has been dominated by Allergan's Restasis

Ophthalmic Approvals

Freeze Lift Allows Cel-Sci And Ergomed Motor On With Multikine

The biggest Phase III trial in head and neck cancer is resuming after the FDA lifted a freeze on trials evaluating CEL-SCI's lead asset Multikine in the indication, giving a boost to its commercial prospects.

Clinical Trials Companies

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies

Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.

Financing Business Strategies

Industry In The Middle: Merck's Frazier Takes A Stand, Trump Tweets Back

The US president made what seemed to be a retaliatory statement about high drug prices after Merck CEO Ken Frazier resigned from his jobs council.

Leadership Pricing Debate

Policy & Regulation Explore this Topic

Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way

FDA approval of an antidote for Factor Xa novel anticoagulants would further drive the already strong uptake of J&J/Bayer's Xarelto and Bristol/Pfizer's Eliquis, analysts say.

Cardiovascular Market Intelligence Complete Response Letters

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

Approvals Research & Development

Stem Cell Therapy Gets Boost With NICE Nod For Chiesi's Holoclar

Single treatment for one eye costs £80,000 but Chiesi is offering a discount for Europe's first approved stem cell medicinal product.

Regenerative Medicine Reimbursement

The Eyes Have It For Shire With Lifitegrast Filing In Europe

The drug, marketed across the Atlantic as Xiidra, has already made significant inroads in the US dry eye market which has been dominated by Allergan's Restasis

Ophthalmic Approvals

Research & Development Explore this Topic

Early Stage Science: Micromotors Open Way For Acid-Sensitive Drug Delivery To GI Tract

Scrip scans for early stage research that could lead to novel treatments or changes in therapy, recently published in major science journals; it finds a new way to deliver acid-sensitive drugs to the GI tract.

Research & Development Gastrointestinal BioPharmaceutical

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

Approvals Research & Development

Mateon's CA4P Disappoints At Second Interim Analysis, More Data Awaited

A third interim analysis, in September, may clarify whether Mateon’s vascular disrupting agent is likely to be therapeutically useful as a new class of agents for ovarian cancer.

Clinical Trials Companies

Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies

South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.

Research & Development South Korea
UsernamePublicRestriction

Register

Advertisement